Scientific Publications

30 June 2021

In VitroEvaluation of the Biosafety of Hyaluronic Acid PEGCross-Linked with Micromoleculesof Calcium Hydroxyapatite in Low Concentration

Open Access Macedonian Journal of Medical Sciences. 2018 January 07.

Nicola Zerbinati, Torello Lotti, Damiano Monticelli, Raffaele Rauso, Pablo GonzálezIsaza, Edoardo D’Este, Alberto Calligaro, SabrinaSommatis, Cristina Maccario, Roberto Mocchi, Jacopo Lotti, Uwe Wollina, Georgi Tchernev, Katlein França


OBJECTIVE: NeauviaStimulate is biocompatible, injectable hyaluronic acid (HA) filler (26 mg/ml) PEG cross-linked with 1% of calcium hydroxyapatite (CaHA) for facial soft-tissue augmentation that provides volume to tissues, followed by process ofneocollagenesisfor improving skin quality.

AIM: The aim of the present study isto evaluate the biosafety of the product (Lot. 160517-26-1/2 PEG) on human keratinocytes cultured in vitro.

MATERIAL AND METHOD: The experimental model proposed, despite being an in vitro system, allows the derivation of useful information to predict the possible activity of the product in further in vivo application. Human keratinocytes (HaCaT cells) were treated with the product for 24h at increasing concentrations of product respect to control (untreated cells).

RESULTS: The biosafety of the product to be tested has been evaluatedperforming different methods: MTT test, NRU test, Kenacid Blue assay. Moreover, any possible effect on the structure, morphology, and viability of cells has been evaluated.

CONCLUSIONS: In conclusion, the results obtained by the different methods show that the product Neauvia Stimulate® does not cause any cytotoxic effect and does not affect the correct structure and morphology of cells cultures.

Download the PDF>

Compile the form here to register
Those credentials are not valid!


Subscribe to the newsletter to receive the scientific and training updates from Neauvia

* indicates required
Compile the form here to request a reset
Those credentials are not valid!